Skip to main content
MedPathMedPath Home
Clinical Trials/ACTRN12611000146998
ACTRN12611000146998
Recruiting
未知

Predictors of Response to Therapy in New-Presentation Idiopathic Dilated Cardiomyopathy

Professor Joseph Selvanayagam0 sites200 target enrollmentFebruary 8, 2011
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsIdiopathic Dilated CardiomyopathyCardiovascular - Other cardiovascular diseases

Overview

Phase
未知
Intervention
Not specified
Conditions
Idiopathic Dilated Cardiomyopathy
Sponsor
Professor Joseph Selvanayagam
Enrollment
200
Status
Recruiting
Last Updated
6 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
February 8, 2011
End Date
TBD
Last Updated
6 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Professor Joseph Selvanayagam

Eligibility Criteria

Inclusion Criteria

  • •Clinical heart failure (New York Heart Association class II \- IV) on first presentation, LV ejection fraction \<45% as measured by echocardiography, ventriculography, or cardiac
  • •scintigraphy

Exclusion Criteria

  • •Standard MRI contraindications, including permanent pacemaker, implantable defibrillator,
  • •severe claustrophobia, Significant coronary artery disease, as manifest by \>70% stenosis in a major epicardial
  • •coronary artery or the presence of a moderate or greater zone of ischaemia/infarction on
  • •stress imaging, Concomitant valvular heart disease as a cause or central contributor to the heart failure
  • •(excluding functional mitral regurgitation, Hypertrophic obstructive cardiomyopathy, Myocarditis, amyloidosis, sarcoidosis, uncontrolled thyroid disease, post\-partum
  • •cardiomyopathy, Renal impairment (eGFR \<60ml/min) will be an exclusion criterion from the administration
  • •of gadolinium, New York Heart Association class IV symptoms (i.e. dyspnoea at rest), and unstable
  • •ischaemic heart disease will be exclusion criteria from cardiopulmonary exercise testing

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Not Applicable
Prediction of therapy response and treatment outcomes in early course of schizophrenia.Subproject D1_AP2 of the research network ESPRIT (Enhancing Schizophrenia Prevention and Recovery through Innovative Treatments)DSM IV-TR:295.10-30, 295.90: Schizophrenia High Risc State of transmission to psychosis
DRKS00010936Klinik und Poliklinik für Psychiatrie und Psychotherapie,LVR-Klinikum Düsseldorf / Kliniken der Heinrich Heine Universität Düsseldorf600
Completed
Not Applicable
Prediction of the therapeutic response and adverse events to methotrexate by monitoring methotrexate-polyglutamates (MTX-PGs) concentration in erythrocytes in Japanese patients with rheumatoid arthritis (RA).
JPRN-UMIN000020134Jichi Medical University56
Completed
Not Applicable
Early clinical and biomarker responses after treatment in patients with non-segmental vitiligoVitiligo10035023
NL-OMON48618Academisch Medisch Centrum36
Recruiting
Not Applicable
A prospective study of treatment response of patients with myelofibrosis and PNH type blood cellsmyelofibrosis
JPRN-UMIN000045859Juntendo University100
Completed
Not Applicable
Genetic Markers of Response to Newer Therapies for Type 2 DiabetesE11Type 2 diabetes mellitus
DRKS00034478Faculty of Medicine, University of Ljubljana161